Archives: Speakers

Mary is part of the Retail Banking Product Management leadership team at Finastra; within the Retail International division.  Originally from Dublin, now based in the UK, Mary previously worked for several banks and technology vendors.  Prior to her current role, Mary worked in most aspects of the banking technology business including marketing, product training, pre-sales and consultancy.  She has project managed a greenfield implementation in Slovakia and a transformation project at a prestigious UK private bank. Mary has also had a very successful sales career looking after some of Finastra’s largest European clients; winning company Salesperson of the year in 2005, and receiving a CEO award in 2014, for outstanding contribution to the business.  With her many years of banking, accounting and industry experience, Mary is well positioned to support Finastra’s efforts to drive their move to Digital Banking in the Cloud.

As a Senior Executive Manager with almost 30 years of work experience within the ICT industry, He is in charge to lead InfoCert’s business expansion across EU and LATAM Markets. On top of the technical and commercial background, he has added strong financial and managerial skills, developed on the job in an international multicultural environment all over the years and by attending multiple training courses, most of them held at the Ashridge Management College of Berkhamsted.

Andrew Thompson is the Director of Therapy and Analysis at GlobalData Healthcare, responsible for data collection and forecasting within the Medical Devices portfolio. Andrew is passionate about developing innovative approaches to the world of medical devices industry research. Andrew joined the team in 2012, following 20 years working within the academic and industry sectors, developing a specialty in advanced diagnostics for infectious disease. With multiple patents in molecular detection technologies, publications’ covering a breadth of topics and leading product development teams, Andrew has established a strong reputation within molecular diagnostics. Having worked on the frontline, Andrew can share a global understanding of the medical device industry, with both a highly developed understanding of the technologies, new and emerging, and of the business dynamics fueling medical device usage in healthcare.

Responsible for the content and direction of global medical device portfolios, GlobalData forward-looking approach generates stimulating analysis and reports, to explore what these changes mean for GlobalData’s clients and their customers.

Professor of Clinical Diabetes and Metabolism, Cardiff University School of Medicine. Professor of Endocrinology and Diabetes, University of Bristol.

Colin Dayan trained in medicine at University College, Oxford, and Guy’s and Charing Cross Hospitals in London, UK before obtaining a PhD in the immunology of Graves’ Disease in Laboratory of Marc Feldmann. He then spent a year as an endocrine fellow at the Massachussetts General Hospital in Boston, USA before completing his specialist training in diabetes and endocrinology as a Lecturer in Bristol. He became a consultant senior lecturer in medicine (diabetes/endocrinology) at the University of Bristol in 1995 and Head of Clinical Research at the Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology in Bristol in 2002. In 2010, he was appointed to the Chair of Clinical Diabetes and Metabolism and Head of Section at Cardiff University School of Medicine. He served as Director of the Institute of Molecular and Experimental Medicine in 2011 – 2015. In 2017 he was appointed to the post of Professor of Endocrinology and Diabetes at the University of Bristol, UK as a joint post with Cardiff.

He has a long established interest in translational research in the immunopathology of type 1 diabetes and is currently conducting early phase clinical trials in the development of antigen specific immunotherapy as well as leading multicentre phase 2 studies. His clinical interests in diabetes include management of poor compliance in type 1 diabetes, public health measures in the prevention of type 2 diabetes and models of community care in diabetes. He is the lead for diabetes in the Cardiff whole pancreas transplantation programme and with colleagues leads an All Wales anonymised data linkage programme for monitoring childhood type 1 diabetes. He has been part of 2 major EU FP7 programme grants in type 1 diabetes (and coordinator on one), a member of the Juvenile Diabetes Research Foundation Medical and Scientific Committee and the Welsh Diabetes Research Unit. Prof Dayan currently leads the Clinical Engagement and Training Core of the Diabetes UK funded type 1 diabetes UK immunotherapy Consortium which aims to coordinate and support combined efforts to bring immunotherapy for type 1 diabetes into clinical practice. He also chairs the UK Clinical Studies Group for the prevention, targets and therapies in type 1 diabetes.